Platform Overview
Features
Cardiac AmyloidosisHeart FailureAortic StenosisPulmonary HypertensionStrain
Operations
Operational ImpactIT & ProcurementReimbursementsCore Lab SolutionsEHR Mining
Clinical Evidence
Our StoryCareersMedia Kit
NewsContact Us Login Book a Demo

About Us2.ai

We're building AI that makes expert-level cardiac diagnostics accessible to healthcare providers worldwide.

AI-Driven Cardiac Insights for Clinicians

Us2.ai combines advanced artificial intelligence with deep clinical expertise to automate echocardiography analysis, enabling faster, more accurate diagnoses. While other tools automate single measurements or require manual frame selection, Us2.ai is the only FDA-cleared platform that delivers a complete structured echo report: measurements, disease detection, and clinical findings, fully automatically.

Mission & Vision

Guided by our commitment to improving cardiovascular care worldwide.

Our Mission

To democratize expert-level cardiac diagnostics by developing AI solutions that make echocardiography analysis faster, more accurate, and accessible to healthcare providers of all sizes worldwide.

Our Vision

A world where every patient has access to timely, accurate cardiac assessment regardless of geography or resource constraints. Where AI augments clinical expertise to save lives and improve outcomes.

Our Journey

Key milestones in our mission to transform cardiac care.

2017
Founded in Singapore as eko.ai by James Hare, Dr. Carolyn Lam, and Dr. Yoran Hummel
2019
$4.5M Seed round led by Sequoia India and EDBI. Grand Prize at SLINGSHOT 2019.
2020
Research partnerships with AstraZeneca and Janssen for heart failure and pulmonary hypertension
2021
FDA 510(k) clearance for Us2.v1, the first fully automated echo decision support tool. Renamed to Us2.ai.
2022
$15M Series A led by IHH Healthcare. CE Mark (Class IIb) achieved. Landmark validation in The Lancet Digital Health.
2023
OPERA study presented at ESC. AI-assisted echo shown as effective as expert standard. Duke University partnership announced.
2024
FDA clearance for Us2.v2 with comprehensive parameters including strain imaging. AI-ECHO RCT presented at AHA.
2025
Fujifilm OEM integration. FDA clearance for cardiac amyloidosis detection. Partnerships with deepc, Harrison.ai, and Merative Merge.
2017
2019
2020
2021
2022
2023
2024
2025

Backed By

Supported by leading healthcare and technology investors.

Series A Lead. Asia's largest private healthcare group.
Seed Lead. Global venture capital.
Seed Co-Lead. Singapore's strategic investment arm.
Deep tech venture builder backed by Singapore government

Leadership Team

A diverse team of clinicians, engineers, and industry leaders building the future of cardiac AI.

James Hare
James Hare
CEO and Co-founder
Dr. Yoran Hummel
Dr. Yoran Hummel
President and Co-founder
Dr. Carolyn Lam
Dr. Carolyn Lam
Co-founder & Non-Exec Head of Medical Affairs
Matthew Frost
Matthew Frost
Head of Data Science
Mathias Iversen
Mathias Iversen
Head of Engineering
Seth Koeppel
Seth Koeppel
Head of Business Development
Shao Yin Tai
Shao Yin Tai
Head of Finance
John Barney
John Barney
IT Operations Manager
Andrie Ochtman
Andrie Ochtman
Technical Program Manager

Medical Advisory Board

World-renowned cardiologists guiding our clinical and scientific direction.

Dr. Martin Cowie
Dr. Martin Cowie
Professor of Cardiology, Imperial College London
Dr. Bijan Dorri
Dr. Bijan Dorri
MedTech Advisor, A*STAR Singapore
Dr. Ken Stein
Dr. Ken Stein
SVP & Global Chief Medical Officer, Boston Scientific
Dr. Jeremy Lim
Dr. Jeremy Lim
Director, Leadership Institute for Global Health Transformation, NUS
Dr. Scott Solomon
Dr. Scott Solomon
Professor of Medicine, Harvard Medical School / Brigham and Women's Hospital
Dr. Justin Ezekowitz
Dr. Justin Ezekowitz
Professor of Medicine & Director of Cardiovascular Research, University of Alberta

See Us2.ai in Action

See how Us2.ai can improve diagnostic accuracy and speed up your echo reporting.

Book a Demo